Trial Information
Special Drug Use Investigation of Zevalin
Inclusion Criteria:
- Patients who received In-111 Zevalin to verify that expected biodistribution is
present.
Exclusion Criteria:
- Patients who are contraindicated based on the product label.
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
Assessment of abnormal distribution of In-111 Zevalin by the investigator [Two scales; Yes or No]
Outcome Time Frame:
At 48-72 hours after In-111 Zevalin injection
Safety Issue:
No
Principal Investigator
Bayer Study Director
Investigator Role:
Study Director
Investigator Affiliation:
Bayer
Authority:
Japan: Ministry of Health, Labor and Welfare
Study ID:
15043
NCT ID:
NCT01479387
Start Date:
August 2008
Completion Date:
February 2011
Related Keywords:
- Non-Hodgkin's Lymphoma (NHL)
- Zevalin
- CD20+
- Non-Hodgkin's lymphoma
- Mantle cell lymphoma
- Lymphoma
- Lymphoma, Non-Hodgkin